AR120540A1 - Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria - Google Patents

Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria

Info

Publication number
AR120540A1
AR120540A1 ARP200103253A ARP200103253A AR120540A1 AR 120540 A1 AR120540 A1 AR 120540A1 AR P200103253 A ARP200103253 A AR P200103253A AR P200103253 A ARP200103253 A AR P200103253A AR 120540 A1 AR120540 A1 AR 120540A1
Authority
AR
Argentina
Prior art keywords
6alkyl
amino
6alkoxy
pyrrolidinyl
piperidinyl
Prior art date
Application number
ARP200103253A
Other languages
English (en)
Inventor
Ge Zou
Wei Zhu
Zhisen Zhang
Hongtao Xu
Xiaoqing Wang
Hong Shen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR120540A1 publication Critical patent/AR120540A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Derivados de 1,8-naftiridin-2-ona que poseen actividad antagonista de TLR7, TLR8 y TLR9, un proceso para su preparación, una composición farmacéutica que comprende a uno de estos compuestos y el uso de los mismos para el tratamiento o profilaxis de enfermedades autoinmunitarias tales como lupus eritematoso sistémico o nefritis lúpica. Reivindicación 1: Un compuesto de la fórmula (1), en donde R¹ es C₁₋₆alquilo; R² es C₁₋₆alquilo; R³ es (C₁₋₆alcoxiC₁₋₆alquil)piperazinilo; (C₁₋₆alquil)₂aminoC₁₋₆alcoxi; 2,5-diazabiciclo[2.2.1]heptanilo; 3,4,4a,5,7,7a-hexahidro-2H-pirrolo[3,4-b][1,4]oxazinilo; 3,8-diazabiciclo[3.2.1]octanilo; 3-oxa-9-azabiciclo[3.3.1]nonanilo; 5-oxa-2,8-diazaespiro[3.5]nonanilo; amino(C₁₋₆alcoxi)piperidinilo; amino(C₁₋₆alcoxi)pirrolidinilo; amino(C₁₋₆alquil)azetidinilo; amino(C₁₋₆alquil)piperidinilo; amino(C₁₋₆alquil)pirrolidinilo; amino-1,4-oxazepanilo; aminohalopirrolidinilo; aminopiperidinilo; C₁₋₆alquil-2,6-diazaespiro[3.3]heptanilo; C₁₋₆alquilpiperazinilo; morfolinilC₃₋₇cicloalquilo; piperazinilo; piperidinilo o pirrolidinilo; o una sal de aquel aceptable desde el punto de vista farmacéutico.
ARP200103253A 2019-11-26 2020-11-24 Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria AR120540A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2019120996 2019-11-26

Publications (1)

Publication Number Publication Date
AR120540A1 true AR120540A1 (es) 2022-02-23

Family

ID=73598065

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200103253A AR120540A1 (es) 2019-11-26 2020-11-24 Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria

Country Status (16)

Country Link
US (1) US20230041743A1 (es)
EP (1) EP4065586A1 (es)
JP (1) JP2023503165A (es)
KR (1) KR20220106126A (es)
CN (1) CN114728987B (es)
AR (1) AR120540A1 (es)
AU (1) AU2020393367A1 (es)
BR (1) BR112022009856A2 (es)
CA (1) CA3156457A1 (es)
CO (1) CO2022006942A2 (es)
CR (1) CR20220231A (es)
IL (1) IL291640A (es)
MX (1) MX2022005912A (es)
PE (1) PE20221026A1 (es)
TW (1) TW202134238A (es)
WO (1) WO2021105072A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4273773A (en) * 1979-09-24 1981-06-16 American Home Products Corporation Antihypertensive tricyclic isoindole derivatives
WO2014123167A1 (ja) * 2013-02-08 2014-08-14 日産化学工業株式会社 ３環性ピロロピリジン化合物及びｊａｋ阻害剤
SI3889145T1 (sl) * 2015-12-17 2024-05-31 Merck Patent Gmbh 8-ciano-5-piperidino-kinolini kot antagonisti tlr7/8 in njihove uporabe za zdravljenje imunskih motenj
EP3601282B1 (en) * 2017-03-30 2021-07-21 F. Hoffmann-La Roche AG Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection
TWI778050B (zh) * 2017-04-21 2022-09-21 美商醫肯納腫瘤學公司 吲哚ahr抑制劑及其用途

Also Published As

Publication number Publication date
JP2023503165A (ja) 2023-01-26
BR112022009856A2 (pt) 2022-08-02
CN114728987B (zh) 2024-08-02
CO2022006942A2 (es) 2022-06-10
CA3156457A1 (en) 2021-06-03
KR20220106126A (ko) 2022-07-28
US20230041743A1 (en) 2023-02-09
WO2021105072A1 (en) 2021-06-03
AU2020393367A1 (en) 2022-04-14
CR20220231A (es) 2022-06-27
IL291640A (en) 2022-05-01
EP4065586A1 (en) 2022-10-05
CN114728987A (zh) 2022-07-08
MX2022005912A (es) 2022-06-24
TW202134238A (zh) 2021-09-16
PE20221026A1 (es) 2022-06-16

Similar Documents

Publication Publication Date Title
GEP20217242B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
CR20200488A (es) Péptidos macrocíclicos contra actinetobacter baumannii
PH12018500904A1 (en) Peptide macrocycles against acinetobacter baumannii
CO2023018119A2 (es) Análogos de triazolo pirimidina para el tratamiento de enfermedades relacionadas con la inhibición de la helicasa recq del síndrome de werner (wrn)
NZ766835A (en) Pharmaceutical compounds
CL2022000271A1 (es) Inhibidores de la fosfatasa shp2 de pirazolo(3,4-b)pirazina.
CR20210504A (es) Compuestos tricíclicos condensados útiles como agentes anticancerígenos
PE20230731A1 (es) Compuestos heterociclicos como inmunomoduladores
SG11201809859VA (en) Benzazepine derivative, preparation method, pharmaceutical composition and use thereof
AR117177A1 (es) DERIVADOS DE 7-(METILAMINO)PIRAZOLO[1,5-A]PIRIMIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE IL-23 E INFa
AR122593A1 (es) Compuestos de dihidroquinolinsulfonamida de ciclopropilo
MX2016015248A (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
CO6270364A2 (es) Derivados de piridina y pirazina utiles en el tratamiento de trastornos de proliferacion celular
PH12020551638A1 (en) Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives
AR102213A1 (es) Inhibidores de la biosíntesis de sulfato de heparano para el tratamiento de enfermedades
AR112283A1 (es) Uso de derivados de aminoalquilbenzotiazepina
DOP2021000045A (es) Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inihibidores de ccr6
PE20181328A1 (es) Compuestos de dihidroquinolinsulfonamida de alquilo
AR106384A1 (es) Derivados de 6-[5-amino-6-(2-etoxietoxi)-imidazo[4,5-b]piridin-3-il]-nicotinonitrilo como inhibidores irak
AR120540A1 (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria
AR090323A1 (es) Imidazopiridazinas sustituidas, procesos e intermediarios para su obtencion y su uso en el tratamiento de enfermedades mediadas por la quinasa mps-1
CL2019003467A1 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias.
EA202190064A1 (ru) Цианотриазоловые соединения и варианты их применения
PH12021551103A1 (en) 1,3,4-oxadiazolone compound and medicine
CL2022002568A1 (es) Derivados de naftiridina y pirido[3,4-c]piridazina como moduladores del receptor gabaa alfa5